Dermoscopic and Histopathological Features of Melanocytic Lesions in Melanoma Patients Undergoing Adjuvant Systemic Therapy

Huseyin Berk Yalcın; Kerem Balan; Ozay Gokoz; Gonca Elcin; Omer Dizdar; Saadettin Kılıckap; Duygu Gulseren

doi:10.5826/dpc.1601a5814

Dermoscopic and Histopathological Features of Melanocytic Lesions in Melanoma Patients Undergoing Adjuvant Systemic Therapy

Authors

Huseyin Berk Yalcın Hacettepe University Department of Dermatology and Venereology
Kerem Balan Hacettepe UniversityDepartment of Dermatology and Venereology https://orcid.org/0009-0009-3438-8844
Ozay Gokoz Hacettepe University Faculty of Medicine, Department of Medical Pathology https://orcid.org/0000-0001-9537-1127
Gonca Elcin Hacettepe University Faculty of Medicine, Department of Dermatology and Venereology https://orcid.org/0000-0001-6292-7272
Omer Dizdar Hacettepe University Faculty of Medicine, Department of Preventive Oncology https://orcid.org/0000-0003-0911-9078
Saadettin Kılıckap Istinye University Faculty of Medicine, Department of Medical Oncology
Duygu Gulseren Hacettepe University Faculty of Medicine, Department of Dermatology and Venereology https://orcid.org/0000-0003-0039-7354

Keywords:

melanoma, adjuvant therapy, Dermoscopy, histopathology, melanocytic nevi

Abstract

Introduction: Melanoma accounts for around 1% of all skin tumors yet is responsible for 80% of deaths related to skin cancer. Although adjuvant therapies improve survival, their effects on nevi remain unclear.

Objectives: This study aimed to investigate the dermoscopic and histopathological features of melanocytic nevi in melanoma patients receiving adjuvant systemic therapy.

Methods: Dermoscopic images of 1,299 melanocytic nevi from 25 melanoma patients undergoing adjuvant therapy (targeted therapy, immunotherapy, or IFN-α) were analyzed before and after treatment. The histopathological features of 129 excised nevi from 67 melanoma patients were compared between patients who received adjuvant therapy and those who did not.

Results: Melanoma patients on targeted therapy showed a greater reduction in global pigmentation and disappearance of the pigment network than those on IFN-α and immunotherapy (p=0.001 and P=0.017, respectively). IFN-α therapy was associated with more atypical pigment network changes than targeted therapy and immunotherapy (P=0.027). Histopathologically, structural atypia, cytological atypia, inflammation, and fibroplasia were more prevalent in excised nevi from patients receiving adjuvant therapy (P=0.003, P=0.004, P<0.001, P=0.020, respectively).

Conclusions: Adjuvant systemic therapy induces dermoscopic and histopathological changes in melanocytic nevi. Clinicians and pathologists should carefully consider these alterations during melanoma follow-up to inform treatment decisions.

References

Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of Melanoma. Med Sci (Basel). 2021 Oct 20;9(4):63. DOI: 10.3390/medsci9040063. PMID: 34698235; PMCID: PMC8544364.

Lazaroff J, Bolotin D. Targeted Therapy and Immunotherapy in Melanoma. Dermatol Clin. 2023 Jan;41(1):65-77. DOI: 10.1016/j.det.2022.07.007. Epub 2022 Oct 28. PMID: 36410984.

Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010 Mar;146(3):265-72. DOI: 10.1001/archdermatol.2010.2. PMID: 20231496; PMCID: PMC3076705.

Zhao CY, Hwang SJE, Wakade D, Carlos G, Anforth R, Fernández-Peñas P. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. Australas J Dermatol. 2017 Nov;58(4):292-298. DOI: 10.1111/ajd.12645. Epub 2017 Jul 14. PMID: 28707403.

Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, Depaepe L, Balme B, Dalle S. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014 May;134(5):1351-1358. DOI: 10.1038/jid.2013.462. Epub 2013 Nov 7. PMID: 24304815.

Zalaudek I, Grinschgl S, Argenziano G, Marghoob AA, Blum A, Richtig E, Wolf IH, Fink-Puches R, Kerl H, Soyer HP, Hofmann-Wellenhof R. Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi. Br J Dermatol. 2006 Feb;154(2):299-304. DOI: 10.1111/j.1365-2133.2005.06973.x. PMID: 16433800..

Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014 Nov;150(11):1209-12. DOI: 10.1001/jamadermatol.2014.838. PMID: 25142409.

Perier-Muzet M, Boespflug A, Poulalhon N, Caramel J, Breton AL, Thomas L, Dalle S. Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma. JAMA Dermatol. 2016 Oct 1;152(10):1162-1164. DOI: 10.1001/jamadermatol.2016.2426. PMID: 27463731.

Burke A, Legesse T. Nivolumab-induced peritonitis with peritoneal mesothelial hyperplasia mimicking metastatic mesothelioma. AJSP Rev Rep. 2022 May-Jun;27(3):98-102. DOI: 10.1097/pcr.0000000000000503. PMID: 35721693; PMCID: PMC9201942.

Aivazian K, Ahmed T, El Sharouni MA, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Ch'ng S, Nieweg OE, Thompson JF, Lo SN, Scolyer RA. Histological regression in melanoma: impact on sentinel lymph node status and survival. Mod Pathol. 2021 Nov;34(11):1999-2008. DOI: 10.1038/s41379-021-00870-2. Epub 2021 Jul 10. Erratum in: Mod Pathol. 2021 Nov;34(11):2091. DOI: 10.1038/s41379-021-00878-8. PMID: 34247192.